Psoriatic Arthritis

Pregnancy in Lupus Nephritis and RA: Managing risks and treating to target A significant proportion of patients with rheumatologic disease are of reproductive age, therefore, navigating reproductive health is now widely recognized as a fundamental component of modern https://t.co/cTVvyXBbug

FDA Approves Tildrakizumab for Psoriatic Arthritis Sun Pharmaceuticals announced Friday that the FDA has approved its IL-23 inhibitor, tildrakizumab (Ilumya) for use in patients with active psoriatic arthritis. https://t.co/9vJoJ35iso https://t.co/4ePITTmPl8

FDA Approves Tildrakizumab for Psoriatic Arthritis | RheumNow

THe the International Federation of Psoriasis Associations has announced that the 8th World Psoriasis & Psoriatic Arthritis Conference will be taking place in Stockholm on 20–22 May 2027. Registration is open. https://t.co/lq5XdcZlki https://t.co/AYGCnwzeue https://t.co/fy6UUCbcxf

This interesting study by @doktora_ging et al describes the notable differences in skin lesions bet Filipino vs caucasian. Fil skin: darker lesions, marked contrast bet hypo/hyperpigmentation, more gray & black psor plaques Practical & informative. @RheumNow #APLAR2026 https://t.co/A1dyFRNkwV

Article

FDA Approves Tildrakizumab for Psoriatic Arthritis

Jack Cush, MD Nov 02, 2026

Sun Pharmaceuticals announced Friday that the FDA has approved its IL-23 inhibitor, tildrakizumab (Ilumya) for use in patients with active psoriatic arthritis. This agent is already FDA approved for plaque psoriasis, and joins guselkumab and risankizumab as the third IL-23 inhibitor

Grappa Symposium: Leung Obesity in PsA - done deal @RheumNow #APLAR2026 https://t.co/3YQT4kiPer

AxSpA+rash vs Axial PsA Kishimoto : two phenotypes of the same disease and to maximise specificity Axis study - imaging criteria = AxSpA phenotype @RheumNow #APLAR2026 https://t.co/UYFnA3AyUM

https://x.com/drpnash/status/2116402903040897383/photo/1

Better drugs only help if patients can get them. In an APLAR PsA registry, 43% of lowest-GDP patients had not reached MDA and were not on a biologic or targeted DMARD. Coverage, reimbursement and social support needed, not just science. P#242 #APLAR26 @RheumNow https://t.co/Rms4QsbcII

https://x.com/JihaRheum/status/2116327499210842589/photo/1

"We really need to ask every patient who has psoriasis about their joints” – Dr. Ahmad Amin, Dermatologist Watch Dr. Amin and Dr. Saakshi Khattri discuss the link between skin and joints in PsA. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/rp2e5oknVF https://t.co/nf2vpvNJuV

PsA Beyond the Joints: Rheum, Derm, and Gastro Perspectives | RheumNow

Prof. Mease shares this important slide illustrating how excessive adipose tissue contributes to PsA dev’t 👇 Dysfunctional adipose tissue enables overall amplification of inflammation in obese pts with PsA @RheumNow #APLAR2026 https://t.co/1YtcqxM4B3

https://x.com/RHEUMarampa/status/2116085070146801824/photo/1

Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic https://t.co/TPqPKP5MRl

Tx persistence & response in PsA is a problem - influenced by demographics & Dz severity. 815 PsA pts in e Brit Society Rheumatology PsA Registe. @12 mos - 24% MDA, 24% ACR50. Median F/U 31 mos, only 65% still on index Rx. D/C higher w/ PDE4i & poorer baseline activity & PROs https://t.co/BhxAMtjsZV

Article

Mixed Drinks, Mixed Results (10.30.2026)

Jack Cush, MD Oct 30, 2026

Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic arthritis

CDR209: A Novel TRBV9×CD3 T Cell Engager for Precision Depletion of Disease-Associated T Cells in Axial Spondyloarthritis https://t.co/RPD7FkgEdQ anti-TRVB and anti-TRAV for your B27 AxSpA patients ( and needs looking at B27 positive PsA ) watch this space

CDR209: A Novel TRBV9×CD3 T Cell Engager for Precision Depletion of Disease-Ass…

number of naive-like CAR-T infused associates with prolonged survival but highly variable APLAR Seoul 2026 #CAR-T #Rheum Now

“Complex to manage” in SLE not for biologics APLAR Seoul 2026 Nikpour #SLE #RheumNow https://t.co/4qeRGEVijs

https://x.com/drpnash/status/2115998694860574864/photo/1

Italian retrospective study of 562 plaque psoriasis Rx w/ biologics - 34% were obese. Primary Rx failure signif. more w/ obesity (17% vs 6%; HR 2.75). A 5 kg/m2 BMI incr assoc w/ 37% higher risk. Lower risk of failure w/ IL-17i (HR 0.49) & IL-23i (HR 0.47). Obesity not assoc w/ https://t.co/fUik6pBcnq

Mark your calendar: RheumNow is covering ACR Convergence 2026, beginning November 7th! Follow along for clinical trial highlights, expert perspectives, daily faculty recaps, livestreams and more. Visit https://t.co/ofGKCCNQnE for the latest coverage. #ACR26 #Rheumatology https://t.co/5p5UxMLu51

Home | RheumNow

Article

Double Trouble (10.23.2026)

Jack Cush, MD Oct 23, 2026

Dr. Jack Cush reviews the journal articles and regulatory announcements from this past week on RheumNow, including: two crystals in one joint, twice the cryptococcus risk in JAKs; Myositis and Scleroderma; and Sjögren’s plus early damage = >> 2 fold risk lymphoma. Double trouble week

The FDA is reviewing Sun Pharma’s tildrakizumab (Ilumya), an IL-23 inhibitor, for use in active psoriatic arthritis, with an October 29, 2026 action (PDUFA) date. Decisons to be based on PsA INSPIRE-1 and INSPIRE-2 Phase 3 Studies https://t.co/iDWhub0k91 https://t.co/j8wQLxNCdA

Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA)…

Polish study compared comorbidities #s in incident RA & PsA. RA pts were older at dx (61 vs 44 yrs) & may drive higher rates in RA. 23/3 comorbidities (74%) were signif more prevalent in RA, including HTN (18 v 12%), ischemic HD (11 v 6%), cerebrovascular dz (4 vs 2%) https://t.co/l0RW6bVVHd

Placebo beats probiotics in PsA. And nearly 90% of well-controlled RA patients may be able to cut their targeted therapy dose in half. Dr. Jack Cush breaks down the findings worth a closer look in this week's RheumNow podcast, Troubles with ‘Gut Feelings’. Probiotics in PsA: https://t.co/Aqy4HxGHbU

Article

‘Tis the Season for Vaccination

Eric Dein, MD Oct 19, 2026

As the leaves start changing color and spooky decorations populate neighborhood doorsteps, another autumnal tradition begins: vaccination counseling. Fall offers a golden opportunity to protect our patients before respiratory viruses fill our waiting rooms. In patients with rheumatologic

Single center study of Probiotics in #PsA showed no benefit. 66 moderately active PsA pts (PASDAS>3.2) on stable Tx: Rx probiotic vs PBO x 12 wks. 56 pts analyzed, PASDAS <3 responders: 43% probiotic vs 65% PBO (P 0.167), w/ no change in gut permeability markers or stool https://t.co/0JUZ8SrRuw

Article

Troubles with ‘Gut Feelings’ (10.16.2026)

Jack Cush, MD Oct 16, 2026

Dr. Jack Cush reviews this week's news from RheumNow.com, including: placebo trumps controversial therapies, the dynamics of disease activity, fuse the big toe, and patients don’t appreciate being told “it's all in your head”!